Searchable abstracts of presentations at key conferences in endocrinology

ea0083ao2 | Adrenal and Cardiovascular | EYES2022

Combining steroid and global metabolome profiling by mass spectrometry with machine learning to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion

A Prete , L Abdi , M Canducci , A. E. Taylor , L. C. Gilligan , A Albors-Zumel , E van den Brandhof , Y Zhang , K. N. Manolopoulos , P Tino , M Biehl , W. B. Dunn , W Arlt

Background: Benign adrenal tumours are discovered in 3-10% of adults and can be non-functioning (NFAT) or associated with adrenal hormone excess, most frequently mild autonomous cortisol secretion (MACS) defined by the failure to suppress cortisol after 1 mg dexamethasone overnight but lack of distinct signs of Cushing’s syndrome (CS). We found that MACS increases the prevalence and severity of type 2 diabetes and hypertension and primarily affects women (Ann Int Med. 202...

ea0019oc14 | Neuroendocrine and Steroids | SFEBES2009

Urinary steroid profiling as a biomarker tool for the detection of adrenal malignancy: results of the EURINE ACC Study

Arlt W , Hahner S , Libe R , Hughes BA , Biehl M , Stiekema H , Schneider P , Smith DJ , Shackleton CHL , Opocher G , Bertherat J , Allolio B , Mannelli M , Mantero F , Fassnacht M , Bertagna X , Stewart PM

Adrenal tumours have an incidence of 2–3% in the general population. Adrenocortical carcinoma (ACC), a highly malignant tumor with a poor prognosis, has an annual incidence of two per million but representation in pre-selected patient cohorts with adrenal masses undergoing surgery is up to 12%. Differentiating adrenocortical adenomas (ACA) from ACC represents a continuous challenge, with unfavourable sensitivities and specificities provided by tumour size, imaging criteri...